Showing 1 - 5 results of 5 for search 'Zeidan AM' Skip to content
Open Access
  • Home
  • Collections
    • High Impact Articles
    • Jawi Collection
    • Malay Medicine
    • Forensic
  • Search Options
    • UiTM Open Access
    • Search by UiTM Scopus
    • Advanced Search
    • Search by Category
  • Discovery Service
    • Sources
    • UiTM Journals
    • List UiTM Journal in IR
    • Statistic
  • About
    • Open Access
    • Creative Commons Licenses
    • COKI | Malaysia Open Access
    • User Guide
    • Contact Us
    • Search Tips
    • FAQs
Advanced
  • Author
  • Zeidan AM
Showing 1 - 5 results of 5 for search 'Zeidan AM', query time: 0.11s Refine Results
  1. 1
    Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
    Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
    by Lewis R, Bewersdorf JP, Zeidan AM
    Published 2021-01-01
    Get full text
    Article
  2. 2
    Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
    Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
    by Uy N, Nadeau M, Stahl M, Zeidan AM
    Published 2018-04-01
    Get full text
    Article
  3. 3
    Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
    Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
    by Bewersdorf JP, Jaszczur SM, Afifi S, Zhao JC, Zeidan AM
    Published 2019-12-01
    Get full text
    Article
  4. 4
    Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
    Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
    by Abou Zahr A, Saad Aldin E, Komrokji RS, Zeidan AM
    Published 2014-12-01
    Get full text
    Article
  5. 5
    Cost-effectiveness of gilteritinib for relapsed/ refractory FLT3mut+ acute myeloid leukemia
    Cost-effectiveness of gilteritinib for relapsed/ refractory FLT3mut+ acute myeloid leukemia
    by Garnham, A., Pandya, B.J, Qi, C.Z, Shah, M.V, Yang, H., Zeidan, A.M
    Published 2021
    Call Number: Loading...
    Located: Loading...
    View Fulltext in Publisher
    Article
Search Tools: Get RSS Feed — Email this Search

Related Subjects

Aniline Compounds Article CD135 antigen Cost-Benefit Analysis FLT3 protein, human Humans Leukemia, Myeloid, Acute Pyrazines Quality-Adjusted Life Years Recurrence Survival Analysis United States Willingness To Pay acute myeloid leukemia adult adverse event aged aniline derivative azacitidine controlled study cost benefit analysis cost effectiveness analysis cytarabine economics etoposide event free survival fludarabine fms-Like Tyrosine Kinase 3 gene mutation genetics

© 2020 | Services hosted by the Perpustakaan Tun Abdul Razak, | Universiti Teknologi MARA | Disclaimer


Loading...